From Chromatin to Clinic: BET Bromodomain Inhibitors as Novel Disease-modifying Therapies in Heart Failure
Archives of Medicine and Health Sciences · 2026-04 · 14 (2) · 312-316
DOI: 10.4103/amhs.amhs_179_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Medicine and Health Sciences, online erschienen am 18.06.2026. Verfasst von Omar Elsaka. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
With an emphasis on their methods of action, preclinical data, and clinical development, this study attempts to investigate the potential of BET bromodomain inhibitors as innovative disease-modifying treatments for heart failure. Studies on BET bromodomain inhibitors in heart failure preclinical models and clinical trials, as well as investigations into their molecular routes and safety profiles, are included in the inclusion criteria. Studies that do not directly target BET bromodomain inhibitors or have nothing to do with heart failure are excluded. Through chromatin regulation, BET bromodomain inhibitors have shown potential in modifying gene expression and focusing on important pathways implicated in the development of heart failure. Their effectiveness in enhancing heart function and lowering fibrosis has been shown in preclinical research. However, issues including toxicity and the need for optimal dosage present difficulties for practical translation. Future studies should concentrate on reducing adverse effects and clarifying their therapeutic processes in more detail. To sum up, BET bromodomain inhibitors have a lot of promise as a novel treatment approach for heart failure, and more research is necessary to fully reap their therapeutic advantages.
Zitieren
APA
Elsaka, O. (2026). From Chromatin to Clinic: BET Bromodomain Inhibitors as Novel Disease-modifying Therapies in Heart Failure. Archives of Medicine and Health Sciences, 14(2), 312-316. https://doi.org/10.4103/amhs.amhs_179_25
Vancouver
Elsaka O. From Chromatin to Clinic: BET Bromodomain Inhibitors as Novel Disease-modifying Therapies in Heart Failure. Archives of Medicine and Health Sciences. 2026;14(2):312-316. doi:10.4103/amhs.amhs_179_25
BibTeX
@article{Elsaka2026,
author = {Elsaka, Omar},
title = {From Chromatin to Clinic: BET Bromodomain Inhibitors as Novel Disease-modifying Therapies in Heart Failure},
journal = {Archives of Medicine and Health Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {312--316},
doi = {10.4103/amhs.amhs_179_25}
}
EUVIMED